Loading...
Docoh

Ikena Oncology (IKNA)

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

IKNA stock data

Calendar

11 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 49.36M 49.36M 49.36M 49.36M 49.36M 49.36M
Cash burn (monthly) (no burn) 17.96M 6.98M 4.14M 6.48M 5.88M
Cash used (since last report) n/a 53.01M 20.61M 12.21M 19.14M 17.36M
Cash remaining n/a -3.65M 28.75M 37.15M 30.22M 32M
Runway (months of cash) n/a -0.2 4.1 9.0 4.7 5.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 Jun 22 Bonita David P Common Stock Buy Dispose P Yes No 5.37 96,035 515.71K 2,098,097
24 Jun 22 Bonita David P Common Stock Buy Dispose P Yes No 4.37 65,965 288.27K 2,002,062
24 Jun 22 Orbimed Advisors Common Stock Buy Dispose P Yes No 5.37 96,035 515.71K 2,098,097
24 Jun 22 Orbimed Advisors Common Stock Buy Dispose P Yes No 4.37 65,965 288.27K 2,002,062
23 Jun 22 Bonita David P Common Stock Buy Dispose P Yes No 3.71 23,419 86.88K 1,936,097
23 Jun 22 Orbimed Advisors Common Stock Buy Dispose P Yes No 3.71 23,419 86.88K 1,936,097
22 Jun 22 Bonita David P Common Stock Buy Dispose P Yes No 3.55 66,806 237.16K 1,912,678
22 Jun 22 Orbimed Advisors Common Stock Buy Dispose P Yes No 3.55 66,806 237.16K 1,912,678
9 Jun 22 Maria Koehler Stock Option Common Stock Grant Acquire A No No 4.85 13,419 65.08K 13,419
9 Jun 22 Richard Wooster Stock Option Common Stock Grant Acquire A No No 4.85 13,419 65.08K 13,419
16.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 50 52 -3.8%
Opened positions 14 9 +55.6%
Closed positions 16 10 +60.0%
Increased positions 6 13 -53.8%
Reduced positions 19 16 +18.8%
13F shares Current Prev Q Change
Total value 192.95M 242.06M -20.3%
Total shares 35.87M 36.57M -1.9%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Atlas Venture Life Science Advisors 5.02M $22.23M 0.0%
FMR 4.4M $19.47M -5.8%
Orbimed Advisors 2.93M $13M 0.0%
Atlas Venture Fund X 2.9M $74.28M 0.0%
BVF 2.5M $11.09M +0.1%
Omega Fund Management 2.25M $9.96M 0.0%
Omega Fund VI 2.25M $0 0.0%
BMY Bristol-Myers Squibb 2.13M $0 0.0%
Citadel Advisors 2.13M $9.42M -0.0%
Biotechnology Value Fund L P 1.8M $0 0.0%
Largest transactions Shares Bought/sold Change
BLK Blackrock 287.75K -1.21M -80.7%
Verition Fund Management 1.02M +1.02M NEW
Laurion Capital Management 529K +529K NEW
Farallon Capital Management 290K -502.08K -63.4%
STT State Street 44.26K -360.35K -89.1%
Point72 Asset Management 688.7K +340K +97.5%
CHI Advisors 1.09M +276.18K +33.9%
FMR 4.4M -268.74K -5.8%
Millennium Management 235.82K +235.82K NEW
Geode Capital Management 102.67K -226.33K -68.8%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: bill, borrow, capacity, debated, hybrid, introduce, introduced, MA, maximum, premium, senior, streamline, subsidiary, unpaid, unresectable
Removed: announced, asset, attendance, closing, consistency, defer, di, discouraging, dose, enzyme, expedite, extracellular, filling, handle, identity, innovative, intangible, interactive, investigate, living, lot, microbial, notified, pace, raw, remote, showing, Slight, spoilage, stability, teleworking, validated, variance, viral